Brigham and Women's Hospital, Seer Filed Patent Complaint
Biotech firms and hospitals are leveraging trade investigations to protect intellectual property from foreign competitors.
Updated on Oct. 8, 2026 in Healthcare
Live Poll
Do you trust that hospital partnerships with biotech firms prioritize patient health over corporate financial interests?
Brigham and Women's Hospital and Seer Inc. have filed a federal patent infringement complaint against Nanomics Biotechnology Co. regarding proteomics kits. The US International Trade Commission is simultaneously reviewing the importation of these kits, as the district court case remains on hold.
Why it matters
Hospitals frequently lack the internal legal resources or capital to enforce intellectual property rights against global competitors. Partnering with biotech firms allows clinical institutions to prove market harm and potentially recoup costs through trade commission enforcement.
Patent enforcement involves significant timelines, with FDA approval processes spanning 10 years and standard patent protection lasting 20 years. Companies facing US International Trade Commission scrutiny may encounter daily non-compliance fees of $100,000.
The players
Brigham and Women's Hospital
A major teaching hospital and biomedical research institution with extensive intellectual property portfolios.
Seer Inc.
A life sciences company focused on proteomics technology development and market commercialization.
Nanomics Biotechnology Co.
A developer and importer of biotechnology products currently facing scrutiny for alleged patent infringement.
US International Trade Commission
A federal agency that investigates and adjudicates trade violations including unauthorized imports of protected technologies.
The details
Biotech firms often partner with hospitals to provide the necessary funding and specialized staff to sustain lengthy patent litigation. While the district court case in Illinois is currently paused, the ITC process serves as a strategic alternative where respondents can face import bans or enter consent agreements to halt product entry into the U.S. market.
Timeline
September 2026: Nanomics Biotechnology Co. refused to participate in the investigation.
End of 2026: The US International Trade Commission is expected to issue a final decision.
Market Landscape
This dispute follows the established pattern set by Section 337 of the Tariff Act, which allows companies to use administrative trade barriers to protect intellectual property. It reflects a broader trend where rights holders supplement federal court litigation with ITC investigations to secure injunctions.
Operators managing intellectual property should factor in the high cost of litigation and the necessity of finding commercial partners to sustain long-term enforcement. Businesses should monitor whether competitors are utilizing ITC proceedings to block market access through import restrictions.
The takeaway
Intellectual property enforcement is a costly, long-term operational commitment that often requires strategic partnerships between research institutions and commercial firms. Monitor the upcoming ITC ruling to see if administrative trade actions replace civil court as the preferred venue for fast-tracking patent protection.
Further reading
For more on industry intellectual property trends, visit Healthcare.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Do you trust that hospital partnerships with biotech firms prioritize patient health over corporate financial interests?
